Episodic transdermal delivery of testosterone

Molecular Pharmaceutics

Volumn 9, Issue 6, 2012, Pages 1537-1543

  Malik, Ritu ^a   Venkatesh, K S ^b   Dwivedi, Anil Kumar ^a   Misra, Amit ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

^b INDIAN INSTITUTE OF TECHNOLOGY KANPUR   (India)

Author keywords

adhesive dispersion; dermatopharmaceutics; nanoparticles; skin permeation

Indexed keywords

ACRYLIC ACID DERIVATIVE; CELLULOSE DERIVATIVE; TESTOSTERONE; VINYL DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; BLOOD LEVEL; CELL HETEROGENEITY; CONTRACEPTION; CONTROLLED STUDY; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RELEASE; FEASIBILITY STUDY; FEMALE; HORMONAL THERAPY; IN VITRO STUDY; LOTION; NONHUMAN; PRIORITY JOURNAL; RAT; TRANSDERMAL PATCH;

ADMINISTRATION, CUTANEOUS; ANIMALS; CHEMISTRY, PHARMACEUTICAL; FEMALE; RATS; RATS, SPRAGUE-DAWLEY; SKIN ABSORPTION; TESTOSTERONE;

EID: 84862023514     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp200558a     Document Type: Article

References (36)

1. Cunningham, G. R.; Toma, S. M. Clinical review: Why is androgen replacement in males controversial? J. Clin. Endocrinol. Metab. 2011, 96 (1), 38-52.
2. Jones, T. H. Effects of testosterone on Type 2 diabetes and components of the metabolic syndrome. J. Diabetes 2011, 2 (3), 146-56.
3. Guay, A.; Traish, A. Testosterone therapy in women with androgen deficiency: Its time has come. Curr. Opin. Invest. Drugs 2011, 11 (10), 1116-26.
4. Nieschlag, E. The struggle for male hormonal contraception. Best Pract. Res., Clin. Endocrinol. Metab. 2010, 25 (2), 369-75.
5. Ellis, G. B.; Desjardins, C. Male rats secrete luteinizing hormone and testosterone episodically. Endocrinology 1982, 110 (5), 1618-27.
6. Malik, R.; Tondwal, S.; Venkatesh, K. S.; Misra, A. Nanoscaffold matrices for size-controlled, pulsatile transdermal testosterone delivery: nanosize effects on the time dimension. Nanotechnology 2009, 19, 435101.
7. Bals-Pratsch, M.; Knuth, U. A.; Yoon, Y. D.; Nieschlag, E. Transdermal testosterone substitution therapy for male hypogonadism. Lancet 1986, 2 (8513), 943-6.
8. Bals-Pratsch, M.; Langer, K.; Place, V. A.; Nieschlag, E. Substitution therapy of hypogonadal men with transdermal testosterone over one year. Acta Endocrinol. (Copenhagen) 1988, 118 (1), 7-13.
9. Findlay, J. C.; Place, V. A.; Snyder, P. J. Transdermal delivery of testosterone. J. Clin. Endocrinol. Metab. 1987, 64 (2), 266-8. (Pubitemid 17001056)
10. Meikle, A. W.; Mazer, N. A.; Moellmer, J. F.; Stringham, J. D.; Tolman, K. G.; Sanders, S. W.; Odell, W. D. Enhanced transdermal delivery of testosterone across nonscrotal skin produces physiological concentrations of testosterone and its metabolites in hypogonadal men. J. Clin. Endocrinol. Metab. 1992, 74 (3), 623-8.
11. Wang, C.; Iranmanesh, A.; Berman, N.; McDonald, V.; Steiner, B.; Ziel, F.; Faulkner, S. M.; Dudley, R. E.; Veldhuis, J. D.; Swerdloff, R. S. Comparative pharmacokinetics of three doses of percutaneous dihydrotestosterone gel in healthy elderly men - a clinical research center study. J. Clin. Endocrinol. Metab. 1998, 83 (8), 2749-57. (Pubitemid 28493771)
12. Nizar, H.; Balasanthiran, A.; Morganstein, D.; Norman, B.; Shotliff, K. Transdermal testosterone gel. Don't take blood from the arm where gel is applied. Brit. Med. J. 2010, 341, c4014.
13. Kathiresan, A. S.; Carr, B. R.; Attia, G. R. Virilization from partner's use of topical androgen in a reproductive-aged woman. Am. J. Obstet. Gynecol. 2011, 205 (3), e3-4.
14. Raynaud, J. P.; Legros, J. J.; Rollet, J.; Auges, M.; Bunouf, P.; Sournac, M.; Fiet, J. Efficacy and safety of a new testosterone-in-adhesive matrix patch applied every 2 days for 1 year to hypogonadal men. J. Steroid Biochem. Mol. Biol. 2008, 109 (1-2), 168-76.
15. Raynaud, J. P.; Aumonier, C.; Gualano, V.; Betea, D.; Beckers, A. Pharmacokinetic study of a new testosterone-in-adhesive matrix patch applied every 2 days to hypogonadal men. J. Steroid Biochem. Mol. Biol. 2008, 109 (1-2), 177-84.
16. Asscheman, H.; Gooren, L. J. Scrotal testosterone patches: a good addition to therapeutic options for hypogonadal men. Ned. Tijdschr. Geneeskd. 2000, 144 (18), 847-50. (Pubitemid 30243348)
17. Misra, A.; Pal, R.; Majumdar, S. S.; Talwar, G. P.; Singh, O. Biphasic testosterone delivery profile observed with two different transdermal formulations. Pharm. Res. 1997, 14 (9), 1264-8. (Pubitemid 27432554)
18. Chik, Z.; Johnston, A.; Tucker, A. T.; Chew, S. L.; Michaels, L.; Alam, C. A. Pharmacokinetics of a new testosterone transdermal delivery system, TDS-testosterone in healthy males. Br. J. Clin. Pharmacol. 2006, 61 (3), 275-9. (Pubitemid 43382626)
19. Kuhnert, B.; Byrne, M.; Simoni, M.; Kopcke, W.; Gerss, J.; Lemmnitz, G.; Nieschlag, E. Testosterone substitution with a new transdermal, hydroalcoholic gel applied to scrotal or non-scrotal skin: a multicentre trial. Eur. J. Endocrinol. 2005, 153 (2), 317-26. (Pubitemid 41167490)
20. Leichtnam, M. L.; Rolland, H.; Wuthrich, P.; Guy, R. H. Enhancement of transdermal testosterone delivery by supersaturation. J. Pharm. Sci. 2006, 95 (11), 2373-9. (Pubitemid 44726378)
21. Misra, A.; Raghuvanshi, R. S.; Ganga, S.; Diwan, M.; Talwar, G. P. Singh Om. Formulation of a transdermal system for biphasic delivery of testosterone. J. Controlled Release 1996, 39 (1), 1-7. (Pubitemid 26139806)
22. Lin, S.; Xing, Q. F.; Chien, Y. W. Transdermal testosterone delivery: comparison between scrotal and nonscrotal delivery systems. Pharm. Dev. Technol. 1999, 4 (3), 405-14. (Pubitemid 29352899)
23. Beiner, M.; Rengarajan, G. T.; Pankaj, S.; Enke, D.; Steinhart, M. Manipulating the crystalline state of pharmaceuticals by nanoconfinement. Nano Lett. 2007, 7 (5), 1381-5. (Pubitemid 46834427)
24. Bravo-Osuna, I.; Ferrero, C.; Jimenez-Castellanos, M. R. Drug release behaviour from methyl methacrylate-starch matrix tablets: effect of polymer moisture content. Eur. J. Pharm. Biopharm. 2008, 69 (1), 285-93. (Pubitemid 351467162)
25. Addicks, W. J.; Flynn, G. L.; Weiner, N.; Chiang, C. M. Drug transport from thin applications of topical dosage forms: development of methodology. Pharm. Res. 1988, 5 (6), 377-82.
26. Addicks, W. J.; Flynn, G. L.; Weiner, N. Validation of a flow-through diffusion cell for use in transdermal research. Pharm. Res. 1987, 4 (4), 337-41.
27. Cichon, R.; Janicki, S. Effect of polyoxyethylene glycols (PEG) on properties of the matrix model of transdermal therapeutic system (TTS) with testosterone. Pharmazie 1991, 46 (10), 719-23.
28. Usher, K. M.; Simmons, C. R.; Dorsey, J. G. Modeling chromatographic dispersion: a comparison of popular equations. J. Chromatogr., A 2008, 1200 (2), 122-8.
29. Siepmann, J.; Siepmann, F. Modeling of diffusion controlled drug delivery. J. Controlled Release 2011, DOI: 10.1016/j.jconrel.2011.10.006.
30. Lee, P. I. Diffusional release of a solute from a polymeric matrix - approximate analytical solutions. J. Membr. Sci. 1980, 7 (3), 255-275. (Pubitemid 11192791)
31. Ishino, R.; Yoshino, H.; Hirakawa, Y.; Noda, K. Design and preparation of pulsatile release tablet as a new oral drug delivery system. Chem. Pharm. Bull. (Tokyo) 1992, 40 (11), 3036-41. (Pubitemid 23021876)
32. Kim, H.; Fassihi, R. Application of binary polyrner system in drug release rate modulation 2. Influence of formulation variables and hydrodynamic conditions on release kinetics. J. Pharm. Sci. 1997, 86, 323-328. (Pubitemid 27113766)
33. Karavas, E.; Georgarakis, E.; Bikiaris, D. Application of PVP/HPMC miscible blends with enhanced mucoadhesive properties for adjusting drug release in predictable pulsatile chronotherapeutics. Eur. J. Pharm. Biopharm. 2006, 64 (1), 115-26. (Pubitemid 44160659)
34. Shah, A. C.; Britten, N. J.; Olanoff, L. S.; Badalmenti, J. N. Gelmatrix systems exhibiting bimodal controlled release for oral drug delivery. J. Controlled Release 1989, 9 (2), 169-175.
35. Matsumoto, T.; Zografi, G. Physical properties of solid molecular dispersions of indomethacin with poly(vinylpyrrolidone) and poly(vinylpyrrolidone-co-vinyl-acetate) in relation to indomethacin crystallization. Pharm. Res. 1999, 16 (11), 1722-8. (Pubitemid 29530405)
36. Miyazaki, T.; Yoshioka, S.; Aso, Y.; Kojima, S. Ability of polyvinylpyrrolidone and polyacrylic acid to inhibit the crystallization of amorphous acetaminophen. J. Pharm. Sci. 2004, 93 (11), 2710-7. (Pubitemid 39506621)